- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT04864938
Recovery After Critical Covid-19 Infection (RECOVID)
Visão geral do estudo
Status
Condições
Descrição detalhada
Eligible patients who have been treated in the intensive care units of Helsinki University Hospital are invited to participate. Controls are recruited from follow-up clinics, and with announcements in media and websites.
The participants receive an invitation to a follow-up clinic where their experiences from the ICU treatment and recovery will be discussed. The investigators will perform neuropsychologic testing (6 months post-discharge), a telephone interview (3 months) and send written questionnaires (3, 6 and 24 months) to the participants. The participants will undergo MRI imaging of the brain and laboratory tests will be taken. The olfactory function will be tested at a follow-up clinic. Data on the patients´ respiratory function from clinical spirometry and diffusion capacity testing 3 and 6 months after discharge are collected. The patients will perform a 6 min walk test.
Data on coagulation laboratory values will be registered from acute phase and 6 months after discharge. The investigators will also analyse ApoE alleles, neurofilament light and NAD-metabolites and study their correlation with neuropsychologic findings and long term symptoms (up to 5 years after hospital discharge).
Participants will also undergo magnetic resonance imaging of the heart at 6-12 months after the hospital discharge, and laboratory samples, a symptom questionnaire and electrocardiogram are collected. Inflammatory parameters and variables associated with regulating inflammation and coagulation will be analysed.
Clinical data from the acute and post-acute phase and demographic data are collected from the patient data management systems.
The target patient number is 75 intensive care treated patients and 50 control persons in each three control group.
Tipo de estudo
Inscrição (Antecipado)
Contactos e Locais
Locais de estudo
-
-
Capital Province Of Finland
-
Helsinki, Capital Province Of Finland, Finlândia, 00290
- Helsinki university hospital
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Descrição
Inclusion Criteria:
- Age 18-100
- Positive PCR for Sars-CoV-2 (except non-covid controls, who must be negative)
- Native language Finnish or Swedish
- Informed consent to study to study participation
Exclusion Criteria:
- Age under 18
- Pregnant or lactating
- Major neurologic diagnosis (TBI, dementia, stroke, Parkinson´s disease before covid-19)
- Substantially impaired hearing or vision
- Developmental disability.
- No consent to study participation
- Contraindication to MR imaging (such as cardiac pacemaker, allergy to contrast)
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Patients: ICU treated covid-19 patients
Neuropsychologic testing Respiratory function testing, chest x-ray and 6 minute walk test MRI of the brain and heart Laboratory tests Olfactory function tests Neuropsychology questionnaires
|
|
Control group 1, covid-19 patients treated in the regular wards
As above, without 6 minute walk test or routine chest x-ray
|
|
Control group 2, persons with covid-19 without hospitalization
As above, but without respiratory testing
|
|
Control group 3, non-covid controls
As control group 2
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Cognitive function 6 months after hospital discharge
Prazo: 6 months after hospital discharge
|
Global score calculated from three domains: memory, executive functions and attention.Memory: WMS-III Word list delayed recall + WMS-III Logical memory delayed recall + Rey Complex Figure, delayed recall Executive: TMB (time, reversed) + Stroop interference (time, reversed) + FAB score Attention: WAIS-IV Coding + CPT (correct items) + Stroop naming (time, reversed) The global score will be compared with controls and age matched national references
|
6 months after hospital discharge
|
|
Diffusion capacity 6 months after hospital discharge
Prazo: 6 months after hospital discharge
|
Diffusion capacity DLCO results (percentage of predicted) 6 months after ICU treatment for covid-19
|
6 months after hospital discharge
|
|
Incidence of post myocarditis findings in MRI of the heart
Prazo: 6-12 months after hospital discharge
|
Incidence of findings in cardiac MRI indicating previous myocarditis in each group
|
6-12 months after hospital discharge
|
|
Six minute walk test distance
Prazo: 6 months after hospital discharge
|
The distance in meters walked by ICU treated patients in 6 minutes in controlled test environment
|
6 months after hospital discharge
|
|
Restriction in lung function tests
Prazo: 6 months after hospital discharge
|
Restriction in lung function parameters vital capacity and forced vital capacity (z-scores) in measured by spirometry
|
6 months after hospital discharge
|
|
Cerebral microbleeds
Prazo: 6 months after hospital discharge
|
Number and anatomical distribution of cerebral microbleeds in MRI imaging of the brain
|
6 months after hospital discharge
|
|
Plasma matrix metalloproteinases -8, -9 and TIMP-1 6 months after hospital discharge
Prazo: 6 moths after hospital discharge
|
Plasma matrix metalloproteinases -8, -9 and TIMP-1 levels in ng/mL 6 months after hospital discharge
|
6 moths after hospital discharge
|
|
Plasma neurofilament level and its correlation with global score in neuropsychological test battery
Prazo: 6 months after hospital discharge
|
Plasma neurofilament level and its correlation with global score in neuropsychological test battery
|
6 months after hospital discharge
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Correlation ApoE 4 alleles with disease severity
Prazo: 6 months post-covid
|
Laboratory analysis of ApoE alleles and comparison of their frequencies among groups
|
6 months post-covid
|
|
Correlation of cerebral microbleeds with neuropsychological global score
Prazo: 6 moths after hospital discharge
|
Correlation of type and location of cerebral microbleeds with neuropsychological global score
|
6 moths after hospital discharge
|
|
Association of the incidence of cerebral microbleeds with findings in cardiac MRI
Prazo: 6-12 months after hospital discharge
|
Association of the incidence of cerebral microbleeds with findings in cardiac MRI
|
6-12 months after hospital discharge
|
|
Correlation of plasma neurofilament with cerebral microbleeds
Prazo: 6 months after hospital discharge
|
Correlation of plasma neurofilament with cerebral microbleeds in brain MR imaging
|
6 months after hospital discharge
|
|
Correlation of 6 minute walk test heart rate variables with cardiac function
Prazo: 6-12 months after hospital discharge
|
Correlation of heart rate in rest, exercise and 5 minutes after exercise with cardiac output measured in heart MRI
|
6-12 months after hospital discharge
|
|
Correlation of matrix metalloproteinase 9 with diffusion capacity
Prazo: 6 months after hospital discharge
|
Correlation of matrix metalloproteinase 9 (ng/mL) with lung diffusion capacity z-score
|
6 months after hospital discharge
|
Colaboradores e Investigadores
Patrocinador
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Antecipado)
Conclusão do estudo (Antecipado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- HUS/1949/2020
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Covid-19
-
PfizerAtivo, não recrutandoCOVID-19 | Doença de Coronavírus 2019 (COVID-19) | Contágio do covid-19 | Vacinas para o covid-19 | Infecção por SARS-CoV-2, COVID19 | Vacinação COVID-19 | Infecção por SARS-CoV-2, COVID-19 | COVID-19 (doença de coronavírus 2019) | Infecção por SARS-CoV-2 por COVID-19Estados Unidos
-
Eggensberger OHGBavarian Health and Food Safety Authority (LGL)RecrutamentoCondição pós-COVID-19 | Pós COVID-19 | Síndrome pós-COVID-19 | Síndrome longa de COVID-19 | Condição Pós COVID-19 (PCC)Alemanha
-
Shanghai Public Health Clinical CenterAinda não está recrutando
-
Duke UniversityNational Institute on Minority Health and Health Disparities (NIMHD)Concluído
-
Lawson Research Institute of St. Joseph'sCanadian Institutes of Health Research (CIHR); Western University, CanadaRecrutamentoFadiga | Síndrome pós-COVID-19 | Condição pós-COVID-19 | Síndrome pós-COVID | Longo COVID-19 | Longo-COVID | Condição Pós-COVIDCanadá
-
PfizerRecrutamentoDoenças Respiratórias | COVID-19 | Pneumonia | Doenças pulmonares | Doença do coronavírus 2019 | Doença de Coronavírus 2019 (COVID-19) | Contágio do covid-19 | Infecções do Trato Respiratório Superior | Infecção do trato respiratório | COVID-19 (doença de coronavírus 2019) | Infecção por SARS-CoV-2 por COVID-19Bélgica
-
Yang I. PachankisAtivo, não recrutandoInfecção Respiratória COVID-19 | Síndrome de Estresse COVID-19 | Reação adversa à vacina COVID-19 | Tromboembolismo associado à COVID-19 | Síndrome Pós-Cuidados Intensivos COVID-19 | AVC associado à COVID-19China
-
ModeX Therapeutics, An OPKO Health CompanyRecrutamentoCOVID 19 | COVID-19 (Prevenção)Estados Unidos
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios...ConcluídoSequelas pós-agudas de COVID-19 | Condição pós-COVID-19 | Longo-COVID | Síndrome COVID-19 CrônicaItália
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkAinda não está recrutandoSíndrome pós-COVID-19 | Longo COVID | Longo Covid19 | Condição pós-COVID-19 | Síndrome pós-COVID | Condição pós-COVID-19, não especificada | Condição Pós-COVIDHolanda